资讯

MarketBeat on MSN5 天
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...
Eli Lilly stock sell-off was 'overreaction': Analysts
Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity ...
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...
With compounders out of the way, Lilly and Novo go after each other
The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...
NBC DFW4 天
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity ...
Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity ...